Markets:

Overview

News

Currencies

International

Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

2.300 -0.070 (-2.95%)

Streaming Delayed Price Updated: 9:41 AM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally ↗

July 25, 2024

Via Benzinga

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

July 25, 2024

From Enveric Biosciences

Via Business Wire

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

July 15, 2024

From Enveric Biosciences

Via Business Wire

New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies ↗

July 11, 2024

Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety.

Via Benzinga

Topics Intellectual Property

Enveric Biosciences Announces Patent Granted for Drug Candidate

July 10, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

June 25, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences to Participate in BIO International Convention 2024

May 30, 2024

From Enveric Biosciences

Via Business Wire

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024 ↗

May 20, 2024

ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand ↗

May 16, 2024

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the...

Via Benzinga

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 15, 2024

From Enveric Biosciences

Via Business Wire

Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate ↗

May 14, 2024

Via Benzinga

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

May 14, 2024

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 08, 2024

Via Benzinga

Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods ↗

May 08, 2024

The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance.

Via Benzinga

Topics Cannabis

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

May 08, 2024

From Enveric Biosciences

Via Business Wire

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 03, 2024

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 03, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 02, 2024

Via Benzinga

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 ↗

April 01, 2024

ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth ↗

March 27, 2024

Via Benzinga

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

March 26, 2024

From Enveric Biosciences

Via Business Wire

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 19, 2024

Via Benzinga

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 19, 2024

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Via Benzinga

Nasdaq Down 100 Points; US Housing Starts Surge In February ↗

March 19, 2024

U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell...

Via Benzinga

Topics Stocks

Why Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday? ↗

March 19, 2024

Enveric Biosciences announces significant progress with non-binding term sheets signed with a biotech firm for cannabinoid-COX-2 conjugate compounds, targeting joint diseases. These agreements could...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 19, 2024

Via Benzinga

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

March 19, 2024

From Enveric Biosciences

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

All News about Enveric Biosciences, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today